Rare Disease and Orphan Drug Development
There are 7,000 rare diseases impacting 350 million patients worldwide, yet only 300 of these…
Certara2016 年 8 月 3 日
Model-based Meta-analysis: An Innovative Methodology Comes of Age
MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…
Certara2016 年 7 月 14 日
Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients with Renal Impairment
Avibactam is a non-β-lactam β-lactamase inhibitor intended for use as a fixed-dose combination with ceftazidime…
Certara2016 年 7 月 12 日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances
Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…
Certara2016 年 7 月 1 日
Pharmacokinetic Profile of Defibrotide in Patients with Renal Impairment
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable, potentially life-threatening complication…
Certara2016 年 6 月 11 日
Diving into Best Practices for Pooling Clinical Trial Data
Learn the best practices for pooling clinical trial data. Discover how effective data integration enhances…
Certara2016 年 6 月 3 日
Pharmacokinetics and Tissue Elimination of Funixin in Veal Calves
OBJECTIVE To describe plasma pharmacokinetic parameters and tissue elimination of flunixin in veal calves. ANIMALS…
Certara2016 年 6 月 1 日
